staff reporter
Articles Authored by staff reporter
Personalis, Tempus Partner to Commercialize Blood-Based Minimal Residual Disease Test
Tempus will market Personalis' NeXT Personal Dx liquid biopsy while Personalis completes its clinical validation in more indications.
Carisma Therapeutics to Start Phase I Trial of CAR Monocyte in HER2-Positive Cancers
The FDA cleared the firm's investigational new drug application to study its autologous cell therapy CT-0525 in patients with solid tumors overexpressing HER2.
Candel Therapeutics Lays off Half its Workforce, Refocuses on Most Advanced Oncology Programs
By reducing staff and lowering its operating costs, Candel expects to fund operations into the fourth quarter of 2024.
Quest Diagnostics, Scipher Medicine Collaborate on Rheumatoid Arthritis Test
Quest will provide RNA extraction and sequencing services for Scipher's PrismRA test, a blood-based molecular test for predicting patient response to TNF inhibitors.
Autolus Seeks FDA Approval for CAR T-Cell Therapy in B-Cell Acute Lymphoblastic Leukemia
The firm's supplemental biologics license application is based on encouraging data from a Phase II trial in more than 100 patients.
Vertex Nets European Label Expansion for Kaftrio Combo in Younger Cystic Fibrosis Patients
Vertex is also seeking to expand the Kaftrio-Kalydeco combination to cystic fibrosis patients with non-F508del Kaftrio-responsive CFTR mutations.
Arvinas Aims to Raise $350M in Private Placement of Common Stock
The firm developing several precision cancer drugs is selling 12,963,542 shares of common stock and pre-funded warrants to purchase 3,422,380 shares of common stock.
FDA Grants Abeona Therapeutics Priority Review for Wound Healing Cell Therapy Application
The agency will review data submitted by the firm from two trials showing pz-cel's ability to heal wounds for those with COL7A1-mutated recessive dystrophic epidermolysis bullosa.
Syncona Taking Freeline Therapeutics Private; Providing $15M in Financing
The additional funds will allow the company to continue to study its gene therapy in Gaucher disease and GBA1-linked Parkinson's disease.
In Brief This Week: Proteomics International, Children's Hospital of Philadelphia, Bayer
News items for the week of Nov. 20, 2023.